Our vision has always been to provide easy-to-use genomic decision support, with the goal that it would one day become a standard in patient care. I am elated that NorthShore shares this vision.
SEATTLE (PRWEB)
May 21, 2020
For many years, NorthShore University HealthSystem (NorthShore) has been one of the leaders in personalized medicine. In 2016, they implemented ActX Genomic Decision Support inside Epic. Now, NorthShore has partnered with ActX to complete their largest genomics program to date.
NorthShore has taken an additional 10,000 patients through genetic testing as part of the DNA-10K initiative. Once genetic testing was completed, the discrete genetic data was loaded into the ActX platform and made available in Epic, NorthShore’s electronic health record. Prescriptions for select medications ordered inside Epic are checked in real time against the patient’s genetics, and the clinician is alerted if there are issues with side effects, efficacy, or dosing, all in routine Epic workflow. A genomic profile for each patient is built into the Epic medical chart.
DNA-10K has already seen tremendous success, with 99% of NorthShore’s eligible physicians ordering tests for their patients. In an internal survey of physicians who ordered the test for their patients, more than half said the program has already provided a direct clinical benefit to their patients. Plus, 99.8% of tested patients had at least one actionable finding associated with pharmacogenomics, which could become relevant later in life (as new prescriptions are needed).
“At NorthShore our goal is to ensure every patient who can benefit from pharmacogenomics will benefit from it no matter where they are receiving care in the system. We continue to progress on this goal as a part of the Mark R. Neaman Center for Personalized Medicine. ActX has been a key partner to drive pharmacogenomics data into clinical care,” said Mark Dunnenberger, PharmD, director of personalized medicine and pharmacogenomics at NorthShore.
“The ActX platform helps make genomics actionable, a key part of which is pharmacogenomics, in everyday medical practice,” said Dr. Andrew Ury, CEO of ActX. “Our vision has always been to provide easy-to-use genomic decision support, with the goal that it would one day become a standard in patient care. I am elated that NorthShore shares this vision, and we are thrilled to be a part of their genomics program.”
About ActX
ActX is the industry leader in EHR-integrated precision medicine. Our service helps physicians make better decisions about medical treatment, using a patient’s genetic information to guide therapy. The ActX Genomic Service offers proven, tightly integrated, real-time genomic decision support for medication orders and actionable genomic risks, a built in patient Genomic Profile, and the ability to fully customize content.
As medications are ordered, and before the prescription is finalized, medications are checked against the patient’s genetics for efficacy, adverse reactions, and dosing. Extensive evidence based and actionable content is provided as default, customizable content, covering hundreds of genes. You can easily suppress any content or interactions, or add or modify content. The ActX Genomic Service is live at numerous Epic customers. For more information, visit http://www.actx.com, email info@actx.com or call 888-998-2289.
About NorthShore University HealthSystem
NorthShore University HealthSystem (NorthShore) is an integrated healthcare delivery system consistently ranked a Top 15 Major Teaching Hospital in the U.S. Headquartered in Evanston, Illinois, NorthShore includes five hospitals – Evanston, Glenbrook, Highland Park, Skokie and Swedish, 140 care sites and 2,300 physicians, serving over 635,000 patients. For more information, please visit http://www.northshore.org and http://www.swedishcovenant.org.
Share article on social media or email: